The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study.
Matteo Lambertini
No relevant relationships to disclose
Matteo Clavarezza
No relevant relationships to disclose
Francesca Poggio
No relevant relationships to disclose
Simona Pastorino
No relevant relationships to disclose
Annalisa Abate
No relevant relationships to disclose
Claudia Bighin
No relevant relationships to disclose
Paolo Pronzato
No relevant relationships to disclose
Lucia Del Mastro
No relevant relationships to disclose